Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 mutant thioureidobutyronitrile ovarian serous carcinoma sensitive detail...
MAP2K1 Q56_V60del Selumetinib ovarian serous carcinoma predicted - sensitive detail...
BRAF V600E Lifirafenib ovarian serous carcinoma predicted - sensitive detail...
BRAF V600E Trametinib ovarian serous carcinoma predicted - sensitive detail...
EML4 - ALK Alectinib ovarian serous carcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib ovarian serous carcinoma predicted - sensitive detail...
BRAF V600E Binimetinib + Encorafenib ovarian serous carcinoma predicted - sensitive detail...
RAD51C mutant Olaparib ovarian serous carcinoma predicted - sensitive detail...
MAP2K1 F129L Trametinib ovarian serous carcinoma resistant detail...
MAP2K1 F129L Selumetinib ovarian serous carcinoma resistant detail...
MAP2K1 F129L Binimetinib ovarian serous carcinoma resistant detail...
MAP2K1 F129L Refametinib ovarian serous carcinoma resistant detail...
BRAF V600E BGB3245 ovarian serous carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02208375 Phase Ib/II Capivasertib + Olaparib Olaparib + Vistusertib mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Active, not recruiting USA 0
NCT02364713 Phase II Pegylated liposomal doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Gemcitabine MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Active, not recruiting USA 0
NCT02446600 Phase III Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA | CAN 2
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA | FRA 0
NCT02759588 Phase Ib/II GL-ONC1 GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer Completed USA 0
NCT02898207 Phase I Olaparib + Onalespib Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Completed USA 0
NCT02983799 Phase II Olaparib Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status Completed USA | CAN 0
NCT03042702 Phase II thioureidobutyronitrile A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer Completed USA 0
NCT03054298 Phase I HuCART-meso cells Cyclophosphamide CAR T Cells in Mesothelin Expressing Cancers Completed USA 0
NCT03096054 Phase I LY3143921 A CR-UK Phase I Trial of LY3143921 Active, not recruiting GBR 0
NCT03126812 Phase Ib/II Carboplatin + Paclitaxel + Pembrolizumab Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer Completed NLD 0
NCT03134638 Phase I Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 A Study of SY-1365 in Adult Patients With Advanced Solid Tumors Terminated USA | FRA | CAN 0
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Terminated USA | BEL 0
NCT03205176 Phase I AZD5153 Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas Completed USA | CAN 0
NCT03278717 Phase III Olaparib Cediranib + Olaparib Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (ICON9) Unknown status NZL | GBR | CAN | AUS 0
NCT03363867 Phase II Atezolizumab + Bevacizumab + Cobimetinib BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON) Active, not recruiting AUS 0
NCT03402841 Phase III Olaparib Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION) Completed SWE | SVN | ROU | POL | NOR | NLD | ITA | ISR | GBR | FIN | ESP | DNK | CZE | CHE | CAN | BGR | BEL | AUT 1
NCT03414047 Phase II Prexasertib A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer Completed USA | ITA | ISR | GBR | ESP | BEL | AUS 1
NCT03462212 Phase Ib/II Bevacizumab + Carboplatin + Paclitaxel + Rucaparib Carboplatin + Paclitaxel + Rucaparib Bevacizumab + Carboplatin + Paclitaxel Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25) Recruiting ITA 0
NCT03462342 Phase II Ceralasertib + Olaparib Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI) Active, not recruiting USA 0
NCT03531645 Phase II Fulvestrant + Palbociclib Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma Active, not recruiting USA 0
NCT03587311 Phase II Anetumab ravtansine + Bevacizumab Bevacizumab + Paclitaxel Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA | CAN 0
NCT03598270 Phase III Carboplatin + Gemcitabine Niraparib Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab + Niraparib Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) Completed ITA | FRA | ESP | DEU | BEL 0
NCT03602859 Phase III Dostarlimab-gxly + Niraparib Niraparib A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) Active, not recruiting USA | ROU | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL 2
NCT03673124 Phase II Letrozole + Ribociclib Ribociclib and Letrozole Treatment in Ovarian Cancer Active, not recruiting USA 0
NCT03675893 Phase II Abemaciclib + LY3023414 Abemaciclib + Letrozole Abemaciclib + Letrozole + Metformin Abemaciclib + Letrozole + LY3023414 Abemaciclib + Letrozole + Zotatifin RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer Active, not recruiting USA 0
NCT03695380 Phase I Atezolizumab + Cobimetinib + Niraparib Cobimetinib + Niraparib A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer Completed USA | ITA | ESP 0
NCT03840200 Phase Ib/II Ipatasertib + Rucaparib A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. Completed USA | ITA | ESP | AUS 1
NCT03909152 Phase II Onapristone Anastrozole + Onapristone A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone Completed USA 0
NCT03926936 Phase II Fulvestrant FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (FUCHSia) Completed NLD | BEL 0
NCT03955471 Phase II Dostarlimab-gxly + Niraparib Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE) Terminated USA 0
NCT04034927 Phase II Olaparib Olaparib + Tremelimumab Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting USA 0
NCT04092270 Phase I Pegylated liposomal doxorubicin + Peposertib A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients Active, not recruiting USA 0
NCT04095364 Phase III Carboplatin + Letrozole + Paclitaxel Letrozole Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer Recruiting USA | IRL | CAN 2
NCT04196257 Phase I BP1001-A BP1001-A + Paclitaxel BP1001-A in Patients With Advanced or Recurrent Solid Tumors Unknown status USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04209855 Phase III Paclitaxel Pegylated liposomal doxorubicin Mirvetuximab Soravtansine Topotecan A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRalpha) Expression (MIRASOL) Completed USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUS 7
NCT04293094 Phase I AMG 650 Study of AMG 650 in Adult Participants With Advanced Solid Tumors Completed USA | ITA | ESP | CAN | BEL | AUS 1
NCT04296890 Phase III Mirvetuximab Soravtansine A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Completed USA | POL | ITA | ISR | IRL | ESP | DEU | CZE | BGR | BEL | AUS 0
NCT04315233 Phase I Belinostat + Ribociclib Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE) Recruiting USA 0
NCT04374630 Phase II Afuresertib + Paclitaxel Paclitaxel Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II) Completed USA 1
NCT04421963 Phase III Olaparib Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib (ROSY-O) Enrolling by invitation USA | TUR | SWE | SVN | POL | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL 5
NCT04460807 Phase III Exemestane Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer (EXPERT) Terminated ITA 0
NCT04510584 Phase II Atezolizumab + Bevacizumab Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer Withdrawn CAN 0
NCT04575961 Phase II Carboplatin + Pegylated liposomal doxorubicin + Pembrolizumab Carboplatin + Gemcitabine + Pembrolizumab Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (PERCEPTION) Recruiting DEU 0
NCT04586335 Phase I CYH33 + Olaparib Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Terminated USA | AUS 1
NCT04625270 Phase II Defactinib + RO5126766 RO5126766 A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201) Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL 0
NCT04657068 Phase Ib/II ART0380 + Gemcitabine ART0380 Gemcitabine A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT04669002 Phase II NLG207 + Olaparib EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Completed USA | HUN | GBR 0
NCT04703920 Phase I Belinostat + Talazoparib Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer Active, not recruiting USA 0
NCT04729387 Phase III Pegylated liposomal doxorubicin Paclitaxel Alpelisib + Olaparib Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected Active, not recruiting USA | TUR | SVK | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG 8
NCT04739527 Phase I DCP-001 Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment (ALISON) Active, not recruiting NLD 0
NCT04814875 Phase Ib/II ATX101 + Carboplatin + Pegylated liposomal doxorubicin A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy Terminated AUS 0
NCT04893551 Phase I BGB149 A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants Terminated NOR | GBR 2
NCT04918186 Phase II BA3021 + Durvalumab Durvalumab + Mecbotamab Vedotin Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC) Recruiting USA | CAN 0
NCT04931342 Phase II Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors Active, not recruiting USA | TUR | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS 2
NCT05039801 Phase I Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Recruiting USA 0
NCT05057715 Phase I HuCART-meso cells + VCN-01 huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer Active, not recruiting USA 0
NCT05065021 Phase II Bevacizumab + Dostarlimab-gxly + Niraparib Bevacizumab + Niraparib Bevacizumab + Dostarlimab-gxly + Paclitaxel Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor Recruiting CAN 0
NCT05113368 Phase II Fulvestrant + Regorafenib Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer Recruiting USA 0
NCT05114421 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients Active, not recruiting USA 0
NCT05123482 Phase Ib/II AZD8205 First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies Recruiting USA | POL | NLD | ITA | HUN | GBR | ESP | CAN | BEL | AUS 5
NCT05183984 Phase II Carboplatin + Niraparib + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Niraparib Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer (NIRVANA-1) Recruiting ITA | FRA | ESP 3
NCT05229900 Phase I SGN-ALPV A Study of SGN-ALPV in Advanced Solid Tumors Terminated USA | SWE | GBR | ESP | CAN 0
NCT05257408 Phase III Nab-paclitaxel Nab-paclitaxel + Relacorilant Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Active, not recruiting USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | CAN | BRA | BEL | AUS | ARG 1
NCT05295589 Phase II Topotecan Pegylated liposomal doxorubicin Copanlisib + Olaparib Paclitaxel Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Withdrawn USA 0
NCT05329532 Phase Ib/II Modi-1 Modi-1 + Pembrolizumab Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY) Recruiting GBR 0
NCT05358639 Phase I Navitoclax + Olaparib Combination of Olaparib and Navitoclax in Women With HGSC and TNBC Active, not recruiting CAN 0
NCT05397093 Phase I ITIL-306 ITIL-306 in Advanced Solid Tumors Active, not recruiting USA 0
NCT05446298 Phase II ONC-392 + Pembrolizumab ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (PRESERVE-004) Active, not recruiting USA 0
NCT05446870 Phase II Bevacizumab + Docetaxel + MK-4830 + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + MK-4830 + Paclitaxel + Pembrolizumab Bevacizumab + Docetaxel + Paclitaxel + Pembrolizumab Docetaxel + MK-4830 + Paclitaxel + Pembrolizumab Carboplatin + MK-4830 + Paclitaxel + Pembrolizumab Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) Completed USA | POL | ITA | ISR | ESP | CAN | BEL 4
NCT05465941 Phase II PLX038 PLX038 for the Treatment of Patients With Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Recruiting USA 0
NCT05498597 Phase I AMT-151 AMT-151 in Patients With Selected Advanced Solid Tumours Recruiting AUS 1
NCT05544929 Phase I KFA115 KFA115 + Pembrolizumab A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers Recruiting USA | ITA | ESP | DEU | CAN 4
NCT05554367 Phase II Binimetinib + Palbociclib Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial Recruiting USA 1
NCT05601700 Phase III Carboplatin + Paclitaxel Letrozole Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (LEPRE) Recruiting ITA 0
NCT05601752 Phase II ADP-A2M4CD8 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) Recruiting USA | GBR | FRA | ESP | CAN 0
NCT05605509 Phase II Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 RP-6306 in Patients With Advanced Cancer Recruiting CAN 0
NCT05700669 Phase Ib/II AsiDNA + Olaparib Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors Completed USA 0
NCT05759923 Phase I OATD-02 First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours Recruiting POL 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05870748 Phase II Luveltamab Tazevibulin Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Luveltamab Tazevibulin + Pegfilgrastim REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Recruiting USA | NZL | ISR | CAN | AUS 2
NCT05872204 Phase II Abemaciclib + Letrozole Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer (ALEPRO) Recruiting NLD | FRA | BEL 0
NCT05902988 Phase Ib/II VLS-1488 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Recruiting USA 0
NCT05920798 Phase Ib/II FR alpha peptide vaccine + Pembrolizumab A Study of FRaDCs for Ovarian Cancer Recruiting USA 0
NCT05922930 Phase Ib/II TROP2-CAR/IL15-transduced CBNK cells Cyclophosphamide + Fludarabine Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer Recruiting USA 0
NCT05950464 Phase I M1774 + ZEN-3694 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer Recruiting USA 0
NCT05961124 Phase II Niraparib Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer Recruiting CAN 0
NCT05998135 Phase II Atovaquone Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer Recruiting USA 0
NCT06084416 Phase I AMG 650 A Study of Sovilnesib in Subjects With Ovarian Cancer Recruiting USA 0
NCT06136884 Phase I AO-252 A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors Recruiting USA 0
NCT06161025 Phase II Paclitaxel Pegylated liposomal doxorubicin Raludotatug deruxtecan Topotecan Gemcitabine A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | CAN | AUS 5
NCT06180356 Phase II Niraparib Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (ANALLISA) Recruiting ESP 0
NCT06188520 Phase Ib/II AZD8421 + Camizestrant + Palbociclib AZD8421 + Camizestrant + Ribociclib Abemaciclib + AZD8421 + Camizestrant AZD8421 A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1) Recruiting USA | GBR | ESP | AUS 1
NCT06253130 Phase Ib/II IMP1734 A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors Recruiting USA | AUS 2
NCT06255665 Phase I JNJ-79032421 A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors Recruiting ESP 0
NCT06257264 Phase I BG-68501 + Fulvestrant BG-68501 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors Recruiting USA | AUS 1
NCT06305299 Phase I Cyclophosphamide + Fludarabine iC9-CAR.B7-H3 T-cells Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells Recruiting USA 0
NCT06321484 Phase I CIML-NK cells + Nogapendekin alfa inbakicept Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer Recruiting USA 0
NCT06334432 Phase Ib/II NUV-1511 Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors Recruiting USA 0
NCT06377267 Phase II Bevacizumab Bevacizumab + Olaparib Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) (STROBE) Recruiting ESP 0
NCT06394804 Phase II Defactinib + Letrozole + RO5126766 A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer (CHAMELEON) Recruiting USA 0
NCT06433219 Phase II M1774 + Niraparib M1774 + M4076 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) Recruiting USA | POL | ITA | GBR | FRA | ESP | DNK | CHE | BEL 0
NCT06451497 Phase I ZM008 Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06457997 Phase I PHN-010 A Study of PHN-010 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06494150 Phase II Fulvestrant + Nab-rapamycin Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) Not yet recruiting USA 0
NCT06618235 Phase Ib/II THEO-260 Trial of THEO-260 in Ovarian Cancer Patients (OCTOPOD) Recruiting GBR 0
NCT06646627 Phase I B7-H3 CAR T cells Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors Not yet recruiting USA 0
NCT06660654 Phase II Raludotatug deruxtecan A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) Not yet recruiting USA 0